Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor targeted therapy; ATR-12, a genetically modified strain of S. epidermidis, which is in a Phase 1b/2a clinical trial for treating Netherton syndrome, a skin disease; and ATR-01, a genetically modified strain of S. epidermidis that expresses an engineered recombinant human filaggrin protein, which is in the IND-enabling phase for treating ichthyosis vulgaris, a skin disease. It has a joint development agreement with Bayer for the identification and characterization of S. epidermidis strains for topical formulations. Azitra, Inc. was incorporated in 2014 and is headquartered in Branford, Connecticut.…
Azitra, Inc. Announces Q3 2026 Results and Provides Business Updates
Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Azitra (NYSEAMERICAN: AZTR) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 0.5168 USD on 20 November 2026, down 89.5% over 52 weeks. Its 52-week range is 0.5086 USD to 7.630 USD: the price is 93.2% below the high and 1.6% above the low.
Its market capitalisation is 3.13M USD.
Azitra reports return on equity of -288.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 3.44M USD. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health.